Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Koji Haratani"'
Autor:
Masayuki Takeda, Kazuto Nishio, Takayuki Takahama, Hidetoshi Hayashi, Kazuko Sakai, Takeshi Yoshida, Kazuhiko Nakagawa, Shinichiro Suzuki, Hiroyasu Kaneda, Kaoru Tanaka, Ryoji Kato, Koji Haratani, Yoshikane Nonagase, Junko Tanizaki, Kimio Yonesaka
Publikováno v:
International Journal of Clinical Oncology. 26:1628-1639
We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M–positive non–small cell lung cancer (NSCLC)
Autor:
Toshihide Yokoyama, Takashi Yokoi, Satoru Miura, Shunsuke Teraoka, Shuji Murakami, Kazushige Wakuda, Yuko Oya, Motohiro Tamiya, Atsushi Nakamura, Takaaki Tokito, Keisuke Tomii, Kenichi Yoshimura, O. Yamaguchi, Nobuyuki Yamamoto, Satoshi Watanabe, Hiroshige Yoshioka, Tetsuhiko Asao, Shoichi Itoh, D. Fujimoto, Akihiro Tamiya, Hiroshi Yokouchi, Koji Haratani
Publikováno v:
European Journal of Cancer. 150:63-72
Introduction Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by t
Autor:
Shinichiro Suzuki, Kazuya Fukuoka, Hisato Kawakami, Soichi Fumita, Kazuhiko Nakagawa, Hidetoshi Hayashi, Chihiro Sato, Kazuko Sakai, Shigeki Shimizu, Tatsuya Okuno, Koji Haratani, Akihiko Ito, Yoshikane Nonagase, Kazumasa Saigoh, Kimio Yonesaka, Hisashi Handa, Takeshi Yoshida, Masayuki Takeda, Tetsuya Mitsudomi, Kazuto Nishio, Takayuki Takahama, Naoki Takegawa, Satomi Watanabe, Kaoru Tanaka
Publikováno v:
The Oncologist
Background Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive geno
Autor:
Kaoru Tanaka, Ryoji Kato, Hitomi Sakai, Masayuki Takeda, Kimio Yonesaka, Hisato Kawakami, Kazuhiko Nakagawa, Koji Haratani, Hidetoshi Hayashi, Kazuto Nishio, Kazuko Sakai
Publikováno v:
British Journal of Cancer
Background Cancer-associated fibroblasts (CAFs) in the tumour microenvironment (TME) suppress antitumour immunity, and the tyrosine kinase inhibitor nintedanib has antifibrotic effects. Methods We performed a preclinical study to evaluate whether nin
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Autor:
Shuta Tomida, Takashi Ogura, Tadashi Ishida, Shigeki Shimizu, Hidetoshi Hayashi, Koji Haratani, Masayuki Takeda, Junko Tanizaki, Ryoji Kato, Kohsuke Isomoto, Yasutaka Chiba, Akihiko Ito, Kazuhiko Nakagawa, Takashi Niwa, Kaoru Tanaka, Yasushi Fukuda, Toshihide Yokoyama
Publikováno v:
Clinical Cancer Research. 26:2037-2046
Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental Design: We retrospectively identified 138 patients with EGFR-mutated NSCLC who un
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Osamu Nishiyama, Hidetoshi Hayashi, Akiko Sano, Yuji Tohda, Yusaku Nishikawa, Takashi Oomori, Kazuhiko Nakagawa, Shigeki Shimizu, Ryo Yamazaki, Kosuke Isomoto, Koji Haratani, Junko Tanizaki
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
Background The utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The purpose of this study was to examine the findings of bronchoalveolar lavage (BAL) analysis and transb
Autor:
Kimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani, Yoshikane Nonagase, Masayuki Takeda, Tomoaki Hoshino, Hidenobu Ishii, Koichi Azuma, Kaoru Tanaka, Hidetoshi Hayashi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 10, Pp 1928-1935 (2019)
Thoracic Cancer
Thoracic Cancer
Background Non-small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Up
Autor:
Koji Haratani, Yoshikane Nonagase, Hisato Kawakami, Kazuhiko Nakagawa, Ryoji Kato, Naoki Takegawa, Hidetoshi Hayashi, Osamu Maenishi, Junji Tsurutani, Masayuki Takeda, Kimio Yonesaka
Publikováno v:
International Journal of Cancer. 145:3414-3424
Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an unmet clinical need for the treatment of tumors that express HER2 protein in the absence of HE